The initial focus will be on developing a laboratory research instrument. "Because this application does not require approval by the Food and Drug Administration, we could enter the market quickly. Subsequently, we will develop products for the clinical point-of-care market using the same technologies," Glazier said.

In the clinical market, the initial focus will be on patients in intensive care units who, because of a large number of intravenous lines, tubes and catheters, are at high risk for bloodstream infection. The clinical setting is ideal for using MSPR technology because of the need for a hand-held device, a highly sensitive and specific test, and a rapid turn-around time on the test in a life-threatening situation.


Proof of concept has already been demonstrated, showing the remarkable sensitivity of MSPR. This technology is the basis for a patent application by Indiana University Research and Technology Corp., and SpheroSense has negotiated exclusive rights on this technology and expects to extend it through further innovation. Additional applications could include drugs of abuse, influenza screening, biodefense and suspicious "white powder" detectors, among others.

Back to HCB News

More Industry Headlines